By The Numbers

Here’s what you missed this week on Managed Healthcare Executive.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.

Recently reported results from an open-label extension trial show positive safety and efficacy results after 52 weeks of use of the drug for overactive bladder.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.

Zynyz is now FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

Results of a real-world study that included people with hemophilia from 33 countries show that people with hemophilia B, especially those with inhibitors, have the greatest unmet need.